Spectrum of GBA Mutations in Patients with Gaucher Disease from Slovakia: Identification of Five Novel Mutations

Slavomíra Mattošová MSc,1,3 Ján Chandoga MD PhD,1 Anna Hlavatá MD PhD MPH,2 Jana Šaligová MD4 and Danka Maceková PhD1

1Institute of Medical Biology, Genetics and Clinical Genetics, Comenius University Faculty of Medicine, University Hospital Bratislava, Bratislava, Slovakia
2Department of Paediatrics, Comenius University Faculty of Medicine, University Children’s Hospital, Bratislava, Slovakia
3Department of Genetics, Faculty of Natural Sciences, Comenius University in Bratislava, Bratislava, Slovakia
4Children’s Faculty Hospital, Košice, Slovakia

ABSTRACT: Background: Gaucher disease is the most common lysosomal storage disorder and is caused by a deficiency of the enzyme glucocerebrosidase. Enzyme deficiency leads to the accumulation of undegraded substrates, mainly in cells of the monocyte/macrophage lineage, which is responsible for the clinical manifestations of the disease. To date, no study has attempted to identify the mutation spectrum of the glucocerebrosidase gene (GBA) in Slovak patients.

Objectives: To identify mutations in 14 Slovak patients with confirmed glucocerebrosidase deficiency.

Methods: Using molecular genetics methods PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) and direct sequencing of coding region GBA we identified the mutational spectrum in our patients.

Results: Five mutations (N370S, L444P, G377S, D409H and RecNci) accounted for 75% of the mutant alleles. The remaining 25% were rare and probably individual mutations.

Conclusions: The mutational spectrum in our patients is similar to that observed in other European countries and corresponds to a Caucasian population, with N370S, L444P, RecNci being the most common. Interestingly, mutation G377S was more frequent in our patients as compared to other published data. The C4W, L96P, H311N, 745delG and 1127_1128delTT mutations are described here for the first time in Gaucher disease, contributing to the panel of published GBA mutations.

KEY WORDS: Gaucher disease, glucocerebrosidase, GBA gene, mutation analysis, novel mutations

Gaucher disease is an autosomal recessively inherited disorder caused by the deficiency of enzyme β-glucosidase (glucocerebrosidase, E.C.3.2.1.45), which cleaves the glycolipid glucocerebroside into glucose and ceramide. This leads to the accumulation of glucocerebroside in various tissues, primarily in the monocyte-macrophage cells of the liver, spleen and bone marrow [1].

The clinical presentation is extremely heterogenous. It has been classified, based on the severity of manifestations, into three different clinical forms. Type 1 (non-neuronopathic, MIM 230800) is the most common subtype and is associated with hepatosplenomegaly, bone involvement and hematological abnormalities. Type 2 (infantile, acute neuronopathic, MIM 230900) is the rarest form, and presents with early-onset severe neurological deterioration and gross organomegaly. Death usually occurs before 2 years of age. Type 3 (juvenile, chronic neuronopathic, MIM 231000) is a less acute form with childhood onset and more slowly progressive neurological disease.

The gene encoding glucocerebrosidase (GBA) is localized on chromosome 1q21 and spans 7.6 kb of genomic DNA. It consists of 11 exons and 10 introns. GBA encodes the protein of 497 amino acids. A highly homologous pseudogene (GBAP1) is located 16 kb downstream and is 5.7 kb in length, with the same organization of exons and introns as the functional gene [2]. There is 96% sequence identity between the functional gene and GBAP1. The presence of a pseudogene at the same locus is significant because some mutations in Gaucher disease patients are due to the recombination of GBA and GBAP1. The region surrounding GBA contains seven functional genes and two pseudogenes [3].

More than 350 mutations have been reported in GBA. These include missense and nonsense mutations, small insertions or deletions that lead to frameshifts or in-frame alterations, splice junction mutations, and complex alleles carrying two or more mutations [4]. The frequencies of characteristic mutant alleles vary in different populations. The most frequent mutations are N370S and L444P. These two mutations represent 60–75% of Gaucher disease-causing alleles in most populations. In Ashkenazi Jewish patients, four mutations account for 90% of the disease alleles (N370S, L444P, 84insG and IVS2+1G>A) [5]. In Caucasian populations 60–70% of mutant alleles represent mutations N370S, L444P, RecNciI, RecTL, D409H and IVS2+1G>A [6,7]. The remaining mutations are rare. Identifying GBA mutations is a useful approach to establish
genotype-phenotype correlations and for genetic counseling of patients regarding clinical outcome as well as treatment recommendations.

There is significant phenotypic variation, not only among patients with the same disease type but also among patients with identical genotypes. The known mutations have been classified into three groups according to their phenotypic effect (null, severe and mild). Patients carrying at least one mild mutation (most frequently N370S) have non-neuropathic disease (type 1), while patients carrying two severe mutations, or severe and a null mutation, usually develop neurological symptoms (type 2 and 3) [8]. Homozygosity for null allele is always associated with perinatal death [9].

In the present study we report the biochemical and molecular analysis of 14 patients with Gaucher disease from Slovakia. All patients were diagnosed by determination of glucocerebrosidase activity in peripheral blood leukocytes. The aim of this study was to identify mutations in Slovak patients with Gaucher disease and to compare the spectrum of mutations to that of other populations.

**PATIENTS AND METHODS**

**SAMPLES**

Samples were submitted to our laboratory to confirm the diagnosis of Gaucher disease, which was suspected by the patients’ physicians. The diagnosis was confirmed in 14 patients (7 females, 7 males). Patients 2 and 3 are siblings. Each patient underwent biochemical analysis and mutation analysis of the GBA gene. DNA extraction was performed from blood samples collected into tubes with EDTA using a commercially available kit, MN NucleoSpin Blood-Mini (Macheray-Nagel, Germany). The purity of isolated DNA ranged from 1.7 to 1.9 and the yield on average was 5 µg.

**BIOCHEMICAL ANALYSIS**

Glucocerebrosidase activity in peripheral blood leukocytes was measured according to the method described previously [10], using fluorogenic substrate 4-methylumbelliferyl-β-D-glucopyranoside (final concentration 2 mmol/L), Glycosynth (UK) in the presence of sodium taurocholate (final concentration 0.6%). Protein concentration of the samples was determined by the Lowry method [11] using bovine serum albumin as standard.

**MOLECULAR ANALYSIS**

- **Detection of common mutation**

  All patients were screened for common N370S and L444P mutation using polymerase chain reaction (PCR) amplification, both followed by restriction analysis. Mutation N370S was detected by mismatched PCR amplification using primers described previously [7], followed by XhoI digestion. Mutation L444P was detected by amplification of the corresponding DNA fragment, followed by NciI digestion [12].

- **Amplification of the GBA gene**

  The exonic sequences and most intronic sequences were amplified in three fragments of 1.7–3 kb in length (exons 1–5, 5–7, 8–11), by the use of primers designed to selectively amplify the glucocerebrosidase gene and not the pseudogene sequence as described previously [13]. The reaction mixture contained 100 ng of genomic DNA, 200 µmol/L dNTPs, 2 mmol/L MgCl2, 0.3 µmol/L of each primer, and 0.625 U GoTaq HotStart polymerase (Promega, USA) in a final volume of 25 µl. The amplification conditions were: initiation denaturation at 95°C for 5 min, 30 cycles of PCR with each cycle consisting of denaturation for 45 sec at 95°C, annealing for 45 sec at 60°C, extension for 3 min at 72°C, and final extension for 10 min at 72°C. Then, 10 µl of PCR products were run on 1% agarose gel to verify the amplification. Next, 15 µl of PCR products were purified using fast alkaline phosphatase and exonuclease I before sequencing. The complete coding region of the gene was sequenced on the ABI Prism 3100 Avant Genetic Analyzer using ABI Prism Big Dye Terminator v3.1 Cycle Sequencing Ready Reaction Kit (Applied Biosystems, USA). All identified mutations were confirmed by sequencing with both forward and reverse primers, as described elsewhere [9]. All mutations were validated by restriction digestion of the corresponding PCR products with the appropriate restriction enzyme.

**EVALUATION OF A NOVEL MUTATION**

Novel mutations in the GBA coding region were analyzed using web-based tools, PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) and SIFT (Sorting Intolerant from Tolerant, http://sift.bii.a-star.edu.sg/) to assess their potential pathogenicity.

**RESULTS**

In the 14 Slovak patients the clinical diagnosis was confirmed by biochemical and mutation analysis. According to clinical parameters, 12 patients were classified as type 1 disease, 1 patient as type 2 and 1 patient as type 3. Low residual glucocerebrosidase activity in each patient was confirmed by enzyme assay [Table 1].

**MUTATION ANALYSIS**

In view of these patients’ clinical manifestations of disease and biochemically proved Gaucher disease, we searched for the mutational spectrum of the GBA gene. We identified 11 different GBA mutations: 7 missense, 3 frameshift mutations and 1 recombinant allele [Table 2].

Our study led to the identification of the mutation in 96% alleles (27 from 28 alleles). N370S was the most prevalent mutation, present in 9 patients (9 from 28 alleles). L444P was found in 4 patients (4 from 28 alleles) as an individual muta-
Nucleotides are numbered from the ATG from the A of the first ATG.

Novel mutations are shown in bold.

**GBA mutations are named according to www.hgvs.org/mutnomen.

We identified both mutations in all analyzed patients, except for one. Five mutations (N370S, L444P, G377S, D409H, RecNciI) accounted for 75% of the mutant alleles (21 from 28 alleles). The remaining were probably individual (C4W, H311N, L96P, c.745delG, c.1127_1128delTT). Genotypes of our patients are shown in Table 1. Nine patients (64%) carried at least one copy of the N370S mutation. All patients, except one (who was homozygous for G377S mutation) were compound heterozygotes for identified mutation.

When two mutations were found in a patient, they were assumed to be on separate alleles. This was verified in patients 4, 5, 6, 10 and 11 by showing that each of their parents or their family members were not available for analysis.

Five of the mutant alleles have not been described previously. Three of them are missense mutations (C4W, L96P and H311N) and two are frameshift (c.745delG and c.1127_1128delTT). Deletion of TT at cDNA position 1127_1128 and deletion of G at cDNA position 745 leads to a frameshift with premature termination codon. It would be expected that such structurally different and shorter proteins were non-functional, and that these mutations are therefore disease-causing. In silico evaluation of the novel missense sequence variants using PolyPhen-2 and SIFT predicted that all these novel variants affect protein function. Mutation C4W was found in a patient with type 2 Gaucher disease with the L444P mutation on the second allele. Mutation L96P in exon 4 was found in combination with G377S mutation in a patient.

### Table 1. Characteristics of patients with Gaucher disease from Slovakia

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Gender</th>
<th>Glucocerebrosidase activity (nmol/h.mg proteins)</th>
<th>Genotype</th>
<th>Type of disease</th>
<th>Clinical manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>0.01</td>
<td>N370S/L444P</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>1.7</td>
<td>D409H/L444P</td>
<td>1</td>
<td>Moderate splenomegaly, mild hepatomegaly, pancytopenia</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>0.9</td>
<td>D409H/L444P</td>
<td>1</td>
<td>Severe splenomegaly, moderate hepatomegaly, hypersplenia, skeletal involvement</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>0.37</td>
<td>N370S/G377S</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>0.3</td>
<td>N370S/1127_1128delTT</td>
<td>1</td>
<td>Severe splenomegaly, mild hepatomegaly, pancytopenia, skeletal involvement</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>0.5</td>
<td>N370S/H311N</td>
<td>1</td>
<td>Severe splenomegaly, hypersplenia, mild hepatomegaly, skeletal involvement</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>1.0</td>
<td>G377S/G377S</td>
<td>1</td>
<td>Severe splenomegaly, moderate hepatomegaly, anemia, thrombocytopenia, leukopenia</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>0.11</td>
<td>G377S/L96P</td>
<td>3</td>
<td>Severe splenomegaly, mild hepatomegaly, anemia, pancytopenia, epilepsy</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>0.45</td>
<td>N370S/745delG</td>
<td>1</td>
<td>Pancytopenia</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>0.3</td>
<td>N370S/?</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>0.7</td>
<td>L444P/C4W</td>
<td>2</td>
<td>Severe splenomegaly, anemia, thrombocytopenia, myoclonic seizures with cerebral deterioration</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>1.0</td>
<td>N370S/84G</td>
<td>1</td>
<td>Moderate splenomegaly, mild hepatomegaly, skeletal involvement</td>
</tr>
<tr>
<td>13</td>
<td>F</td>
<td>–</td>
<td>N370S/RecNciI</td>
<td>1</td>
<td>Mild splenomegaly</td>
</tr>
<tr>
<td>14</td>
<td>F</td>
<td>–</td>
<td>N370S/RecNciI</td>
<td>1</td>
<td>Mild splenomegaly</td>
</tr>
</tbody>
</table>

### Table 2. Characteristics of mutations in Slovak patients with Gaucher disease

<table>
<thead>
<tr>
<th>Mutation*</th>
<th>cDNA nucleotide substitution**</th>
<th>Affected exon</th>
<th>No. of alleles</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>N370S</td>
<td>c.1226A&gt;G</td>
<td>9</td>
<td>9</td>
<td>32</td>
</tr>
<tr>
<td>L444P</td>
<td>c.1448T&gt;C</td>
<td>10</td>
<td>4</td>
<td>14</td>
</tr>
<tr>
<td>G377S</td>
<td>c.1246G&gt;A</td>
<td>9</td>
<td>4</td>
<td>14</td>
</tr>
<tr>
<td>D409H</td>
<td>c.1342G&gt;C</td>
<td>9</td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td>C4W</td>
<td>c.1299G&gt;G</td>
<td>3</td>
<td>1</td>
<td>3.5</td>
</tr>
<tr>
<td>L96P</td>
<td>c.404T&gt;C</td>
<td>4</td>
<td>1</td>
<td>3.5</td>
</tr>
<tr>
<td>H311N</td>
<td>c.1048G&gt;A</td>
<td>8</td>
<td>1</td>
<td>3.5</td>
</tr>
<tr>
<td>84GG</td>
<td>c.84dupG</td>
<td>2</td>
<td>1</td>
<td>3.5</td>
</tr>
<tr>
<td>RecNciI</td>
<td>c.1487T&gt;C,c.1485G&gt;C,c.1487G&gt;C</td>
<td>10</td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td>745delG</td>
<td>c.745delG</td>
<td>6</td>
<td>1</td>
<td>3.5</td>
</tr>
<tr>
<td>1127_28delTT</td>
<td>c.1127_1128delTT</td>
<td>8</td>
<td>1</td>
<td>3.5</td>
</tr>
</tbody>
</table>

* GBA mutations are named according to www.hgvs.org/mutnomen.
** Nucleotides are numbered from the ATG from the A of the first ATG.

* Novel mutations are shown in bold.

* Comparable to H311R mutation [22]
with type 3 Gaucher disease. The remaining novel mutations were found in patients with type 1 Gaucher disease with N370S on the second allele.

DISCUSSION

The diagnosis of Gaucher disease in patients with clinical symptoms requires the proof of glucocerebrosidase activity deficiency usually in suspension of leukocytes isolated from venous blood. The glucocerebrosidase activities in all our patients were markedly reduced compared to reference values of controls. After confirming the diagnosis the next step was to identify a mutation in the glucocerebrosidase gene in each patient.

The most prevalent mutation in our patients was N370S. It was found in 32% of all mutated alleles (9/28). This frequency is somewhat lower than that observed in other central European countries [6,14,15]. Frequency of the second most prevalent mutation (L444P) was 14%. This frequency is comparable to that reported in other central European countries [6,14,15]. In Poland, due to a relatively high frequency of type 3 Gaucher disease, L444P is the most frequent mutation, followed by N370S [16]. The other frequent mutations in our patients were G377S, D409H and RecNciI. These above mentioned mutations are the most prevalent in Slovak Gaucher disease patients and accounted for 75% of mutant alleles. Mutation 84GG, one of the most common mutations in Ashkenazi Jewish populations, was found in one allele (1/28). The remaining mutations were rare and probably individual mutations. This mutation profile corresponds to that of other Caucasian populations [6,7,14,15], with the exception of G377S mutation, which was more frequent among our patients as compared to other published data from central Europe. The higher prevalence of this mutation was previously reported in patients from Portugal [17] and Brazil, in whom it is the third most frequent mutation [18,19].

The presence of the N370S mutation was always associated with non-neuronopathic disease. These results are similar to those previously reported, namely, at least one N370S allele can prevent the development of neurological signs [20]. Most of the type 1 patients were compound heterozygotes due mainly to the association of the mild N370S with another mutation. Also mutation G377S is associated with type 1 disease [21], although other reports have detected type 3 patients with one copy of G377S. Two copies of the G377S mutation generate sufficient residual enzymatic activity to prevent neurological involvement, whereas one copy combined with a severe mutation on another allele leads to type 3 Gaucher disease [19]. We report here a patient with type 3 Gaucher disease heterozygous for G377S and a novel L96P mutation. Mutation L444P may be associated with all types of Gaucher disease. In our patients, this mutation was associated with type 1 Gaucher disease in heterozygosity with N370S or D409H mutation. Another patient had novel mutation C4W on the second allele. This patient suffered from type 2 Gaucher disease.

We have identified five novel mutations among our patients (not found in the Human Gene Mutation Database). Two of the novel variants described here are certainly disease-causing mutations, as they create a frameshift and generate a premature stop codon. These mutations were found in patients with type 1 disease with mutation N370S on the second allele. The other three novel sequence variants were missense mutations. Mutation L96P was found with G377S on the second allele in a patient with type 3 Gaucher disease. Mutation H311N was found in combination with N370S mutation on the second allele in a patient with type 1 Gaucher disease. This mutation affects the same amino acid residue as mutation H311R, which most likely means that this missense change is indeed pathogenic. Mutation H311R was previously described in a patient with lethal type 2 Gaucher disease and has been classified as a severe mutation [22].

Mutation C4W was found in a female patient with type 2 Gaucher disease who presented with marked splenomegaly, anemia and thrombocytopenia, myoclonic seizures and cerebral deterioration. She died before reaching 1 year of age. Mutation C4W, which converts the first cysteine in exon 3 to tryptophan, was found with mutation L444P on the second allele. It could be predicted that this mutation has a potential deleterious effect on protein folding and disrupts the first disulphide bond within domain 1 of the X-ray structure of the glucocerebrosidase molecule, thought to be required for correct folding [23]. All cysteines except C126 are necessary for enzyme activity [1]. The loss of cysteine was previously observed in the missense mutation C16S, which resulted in type 2 phenotype [24].

The remaining undefined mutant allele in one patient can be explained by alterations outside the GBA coding region, in the promoter region, in untranslated or in non-coding regions. Such changes would not be detected by our approach.

The results of this study on the biochemical and molecular basis of Gaucher disease in Slovak patients contribute to the mutation spectrum of the GBA gene in European countries. We report five novel mutations causing Gaucher disease. We also supply data on mutations in a Central European population. Slovak patients show a profile characteristic of a European population, with the N370S, L444P and RecNciI mutations being the most prevalent. Interestingly, mutation G377S was frequent in our patients too. Genotype-phenotype correlations confirmed the previously reported protective role of N370S allele against the development of neurological complications. Identification of mutant alleles should help to establish genotype-phenotype correlations to facilitate genetic counseling and molecular analyses for families at risk. Understanding the clinical consequences of the different genotypes in our patients is critical to the establishment of procedures for monitoring and treating this disorder.
Correspondence  
Dr. S. Mattošová  
University Hospital Bratislava, Mickiewiczova 13, 813 69 Bratislava, Slovakia  
phone: (421-2) 572 90 192  
email: smatsosova@gmail.com

References

Capule

Coffee or tea consumption and the risk of rheumatoid arthritis: a meta-analysis

Lee et al. investigated the evidence for a relationship between coffee or tea consumption and the development of RA by performing a meta-analysis of the published results. Five studies (three cohort and two case-control studies) including 134,901 participants (1279 cases of RA and 133,622 non-cases) were considered. Meta-analysis of the cohort studies revealed a trend of an association between total coffee intake and RA incidence (relative risk [RR] of the highest versus the lowest group = 4.148, 95% confidence interval [CI] = 0.792–21.73, P = 0.092). Meta-analysis of case-control studies showed a significant association between total coffee intake and RA incidence (RR = 1.201, 95%CI = 1.058–1.361, P = 0.005). Combining the data of the cohort and case-control studies showed a significant association between total coffee intake and RA incidence (RR = 2.426, 95%CI = 1.060–5.554, P = 0.036). Meta-analysis stratified by seropositivity indicated a significant association between coffee consumption and seropositive RA risk (RR = 1.329, 95%CI = 1.162–1.522, P = 3.5 × 10–5), but not seronegative RA risk (RR = 1.093, 95%CI = 0.884–1.350, P = 0.411). No association was found between tea intake and RA incidence (RR = 0.880, 95%CI = 0.624–1.239, P = 0.463). This meta-analysis of 134,901 participants (most of the participants were controls) suggests that high coffee consumption is associated with an elevated risk of RA development. The association between coffee and RA was found in seropositive RA, but not in seronegative RA.

Clin Rheumatol 2014; 33: 1575
Eitan Israeli

“Who overcomes by force hath overcome but half his foe”

John Milton (1608-1674), English poet, polemicist, man of letters, and a civil servant for the Commonwealth of England under Oliver Cromwell. He wrote at a time of religious flux and political upheaval, and is best known for his epic poem Paradise Lost

170

ORIGINAL ARTICLES

IMAJ • VOL 17 • MARCH 2015